Loading...
Loading...
BLPH| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,085.0K |
| Operating I/L | -5,085.0K |
| Other Income/Expense | 69.0K |
| Interest Income | -67.0K |
| Pretax | -5,016.0K |
| Income Tax Expense | 2,417.0K |
| Net Income/Loss | -7,433.0K |
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company specializing in the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product, INOpulse, is a proprietary pulsatile nitric oxide delivery platform designed for the treatment of pulmonary hypertension. The company is currently focused on advancing INOpulse through Phase 3 clinical trials for various pulmonary hypertension indications, including fibrotic interstitial lung disease, chronic obstructive pulmonary disease, sarcoidosis, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension associated with pulmonary edema from high altitude sickness.
